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and includes sites of high botanical 
interest.
From 2000 to 2004, volunteers 
sent by the environmental charity 
Earthwatch helped to gather 
biodiversity data to back the scientific 
case for the sanctuary. Using this 
research, Earthwatch and NCRC 
demonstrated to the tribal chiefs that 
the creation of a sanctuary would 
provide a profitable alternative to 
unsustainable hunting and fishing. 
Investment was made in infrastructure, 
equipment and training using funds 
from Earthwatch, with the aim of 
leaving behind trained individuals 
from the community to manage the 
sanctuary and providing the facilities 
for an eco-tourism enterprise.
Today the sanctuary realizes annual 
revenue of around $30,000 from 
visiting tourists — which has more 
than offset the costs of creating the 
reserve and has helped the people 
in the region as well as the animals. 
“A total of 15 new jobs have been 
created and 10 non-direct jobs. 
Women have been able to earn an 
independent living through the sale 
of handicrafts,” Mason says. “Today 
all 17 villages have access to clean 
water, whereas only two did before. 
Solar lighting is being installed 
throughout Wechiau communities,  
and the roads have been improved.”
The government of Ghana is not 
involved in the initiative, which is run 
by a local management board, but in 
2005 gave it full endorsement.
In recent years, NCRC has started 
to replicate this approach in five 
other locations in Ghana. Other 
conservation sites include one for 
white-necked rock fowl in the  
Brong-Ahafo region, one for manatees 
at Lake Volta, one for elephants 
and carnivores in Nyankamba and 
a sanctuary for colobus monkeys in 
Boabeng-Fiema. At the Avu lagoon, 
local communities have set aside 150 
square kilometres for the protection of 
the Western sitatunga — the world’s 
only aquatic antelope.
In the Fanteakwa district, the NCRC, 
in collaboration with Earthwatch and 
Cadbury–Schweppes, is setting up 
an eco-tourism initiative designed 
to enhance biodiversity in cocoa 
farming. “Preliminary research results 
indicate that cocoa grown in shaded 
conditions, where native trees are 
retained, substantially improves 
biodiversity on the cocoa farms,” 
says Nat Spring, Head of Research 
at Earthwatch (Europe). “Our long 
term goal is to support wildlife while 
helping Ghana’s farming community 
to boost their livelihoods through a 
combination of improved farming 
practices and eco-tourism.”
The project will introduce visitors to 
Ghana’s cocoa industry and showcase 
the benefits of environmentally 
friendly cocoa farming. Guided visits 
and hiking trips to functioning cocoa 
farms, walking and biking tours and 
camping excursions will be organised 
by the local community. The visitor 
centre will also host lectures about 
cocoa farming, display information 
about the history of chocolate and 
sell locally manufactured souvenirs 
and products. In 2008, the community 
expects to generate over $15,000 
and significantly expand employment 
opportunities. 
John Mason hopes to be able to 
apply NCRC’s community-based 
approach, which has so far been 
highly successful in relatively small-
scale projects, to one existing wildlife 
reserve in 2009 and to a national park 
by 2012. The NCRC is also thinking 
of transferring the approach to other 
West African countries, such as 
Liberia and Sierra Leone.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.ukThe story of the IMP began in the 
early 1980s, when the German 
chemical company Boehringer 
Ingelheim decided to move into 
biotechnology, licensing certain 
products from the American company 
Genentech. In 1985 the resulting 
business arrangement led the two 
firms to the idea of establishing a joint 
laboratory focusing on basic research 
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looks at the development and impact 
of this major lab.
Vienna landmark into cancer. It was decided to site this laboratory in the Austrian capital and 
two eminent scientists, Jeff Schatz 
and Peter Swetly, were charged with 
getting the idea off the ground.
Swetly and Schatz began with a 
search for an appropriate scientific 
director. Their choice fell on Max 
Birnstiel at the University of Zurich. 
Birnstiel had been director of his 
institute for 14 years and had hinted 
that he would welcome a fresh 
challenge, so when Schatz approached 
him he was initially amenable, although 
when he heard that the new laboratory 
was to be in Vienna his interest 
dropped dramatically and his response 
was “No way!”Eastern light: Vienna’s Institute of Molecular Pathology has been at the heart of the city’s life 
science developments. (Photo: IMP/Lembergh.)
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to consider the status of Austrian — 
and particularly Viennese — science 
at the time. In the 1980s, the country 
was still suffering from the brain drain 
caused by the Second World War and 
Vienna was generally seen as the far 
eastern outpost of Western Europe. In 
addition, the infrastructure was hardly 
inspiring. As Birnstiel says: “The 
science departments of the University 
of Vienna were housed in a series of 
antique buildings strewn throughout 
the city and could not really be said to 
be a centre of research excellence.”
Birnstiel was persuaded to 
reconsider by the enthusiasm of 
Schatz and the two companies, who 
had negotiated promises of large-
scale investment from the city and 
the Republic of Austria. He was well 
aware that he was taking a huge 
risk in leaving his tenured position in 
Zurich but felt that the opportunity to 
make his mark on a new institute was 
worth the gamble. And on 1 October 
1986 he officially started his new job.
The IMP is now at the hub of 
a campus that includes the 
Max F. Perutz Laboratories, the 
Austrian Academy of Sciences’ 
Institute for Biotechnology and 
Gregor Mendel Institute and a 
number of spin-off companies
Among his initial tasks was the 
recruitment of five senior scientists 
prepared to relocate to Vienna. His 
approach was “to look around for good 
people who seemed unhappy with their 
present positions”. The well-publicized 
hardship faced by British science 
under the Thatcher government 
suggested that the UK might be a good 
place to start and so Birnstiel spoke to 
Adrian Bird, who was at an MRC unit in 
Edinburgh, and to Kim Nasmyth, then 
at the LMB in Cambridge. Nasmyth 
was ready for a fresh challenge. The 
“best one could hope to do at the LMB 
was as well as one’s predecessors, 
which was highly unlikely,” he said, and 
the idea of moving to a completely new 
institute appealed to him. Nevertheless, 
he made his acceptance conditional 
upon Bird’s decision and this seemed 
to represent a major stumbling block. 
Fate intervened, however, when the 
MRC announced that it planned to close the unit where Bird was working. 
And Bird’s choice became even easier 
when his laboratory building burned 
down. 
Another ‘double pack’ was Hartmut 
Beug and Erwin Wagner, who came 
together from the EMBL in Heidelberg. 
And the line-up of senior scientists 
was completed by Meinrad Busslinger, 
who accompanied Birnstiel from 
Zurich. By early 1988, then, the key 
scientific players had been recruited. 
Simultaneously, the IMP building was 
taking shape. The chosen site was 
a derelict factory building next to an 
abandoned slaughterhouse in Vienna’s 
third district, not exactly close to the 
centre of Vienna’s intellectual life. 
But work proceeded quickly and by 
January 1998 the building was ready 
to open.
Possibly because of the generous 
backing of the two companies, 
the IMP was quick to establish 
itself among the leading institutes 
in the field in Europe. The minor 
hiccup caused by the withdrawal of 
Genentech in 1993 — the weak dollar 
made the company’s investment 
simply impossible to afford — was  
overcome when Boehringer 
Ingelheim agreed to assume sole 
financial responsibility. The IMP’s 
Directors, Birnstiel until 1996, Kim 
Nasmyth from 1997 until 2006 and 
Barry Dickson from 2006, have been 
free to concentrate on science. In line 
with the original aim, a considerable 
amount of effort has been dedicated 
to cancer biology (Wagner and 
Beug are still working on this field 
and Gerhard Christophori was at 
the IMP from 1994 until 2001) but 
Busslinger’s discovery and analysis 
of the Pax5 gene, which regulates 
B-cell development; the work of Bird, 
Denise Barlow (who discovered the 
first imprinted gene) and Thomas 
Jenuwein (who identified histone 
methyltransferases) on epigenetics; 
Nasmyth’s discovery of cohesins 
in yeast, together with Jan-Michael 
Peters’ studies of vertebrate 
cohesins and Michael Glotzer’s 
discovery of the centralspindlin 
complex; and Jürgen Knoblich’s 
analysis of asymmetric cell division 
in Drosophila have all combined to 
ensure that the IMP has been at the 
forefront of developments in a large 
number of areas.
The Institute’s focus has expanded 
over time to include computational 
biology, structural biology, cell biology and neurobiology. As Dickson 
notes, “evolution is one of the 
fundamental principles of life and 
it applies equally well to research 
institutes like the IMP. If we don’t 
evolve constantly we won’t be able 
to stay at the forefront of the field.” 
Together with the expansion in 
scientific scope, the IMP has seen 
a rapid turnover of staff, especially 
among the junior scientists who have 
gone on to key positions elsewhere in 
Austria and further afield.
Nevertheless, a number of senior 
scientists have proven remarkably 
durable. Birnstiel initially offered them 
five-year contracts and expected them 
to leave at the end of this period but, to 
his surprise, “with one exception [Bird, 
who made it clear at the outset that he 
would remain for only three years], they 
all stayed on and on and on.” Birnstiel 
himself only left in 2006, Nasmyth 
moved to the University of Oxford in 
the same year and three very senior 
figures leave shortly: Dickson thus has 
an unusual opportunity to reposition 
the institute. He is currently looking 
to recruit one or two senior scientists, 
particularly in neurobiology, stem cell 
biology and/or oncology. In addition, 
he hopes it will be possible to recruit a  
few younger group leaders, some 
of whom may go on to compete for 
longer-term positions.
In retrospect, the IMP’s scientific 
success may not seem entirely 
surprising. After all, Birnstiel had 
been able to recruit a group of 
elite researchers and to offer them 
generous levels of support. But few 
could have foreseen the dramatic 
changes the IMP would bring to 
science in Vienna. Soon after the 
formal opening, an agreement was 
signed with five university institutes to 
constitute the ‘Vienna Biocenter’. The 
IMP is now at the hub of a campus 
comprising 1,700 people, including 
600 students, that also involves 
the Max F. Perutz Laboratories, 
the Austrian Academy of Sciences’ 
Institute for Biotechnology and Gregor 
Mendel Institute and a number of 
spin-off companies and agencies 
devoted to PR work. As a result, 
Vienna has become one of the leading 
places in Europe for molecular life 
sciences, a stark contrast to the 
situation 20 years ago. 
Graham Tebb was a post-doc at the IMP 
from 1988 to 1990. He is still based in 
Vienna.
